Content about Urology

May 3, 2013
Study finds testicular cancer rates on the rise among males aged 15-34

Rates of testicular cancer among young men have risen significantly over the last two decades across racial and ethnic groups, according to a new study, and researchers are wondering what accounts for it.

SAN DIEGO — Rates of testicular cancer among young men have risen significantly over the last two decades across racial and ethnic groups, according to a new study, and researchers are wondering what accounts for it.

March 20, 2013
TreatMyUTI.com offers online access to physician diagnosis, UTI treatment

A new online service, dubbed TreatMyUTI.com, is offering patients what it says is the first online access to physician diagnosis and treatment of uncomplicated urinary tract infections with no office visit, exam or lab test required.

COLUMBIA, S.C. — A new online service, dubbed TreatMyUTI.com, is offering patients what it says is the first online access to physician diagnosis and treatment of uncomplicated urinary tract infections with no office visit, exam or lab test required.

TreatMyUTI.com was founded by a group of physicians and this plan of diagnosis and urinary tract infection treatment is the first in a series of health issue diagnosis and treatment services that will be offered, the company stated.

October 22, 2012
Astellas bladder drug made available in U.S.

The U.S. subsidiary of Japanese drug maker Astellas Pharma has made a drug for overactive bladder available in U.S. pharmacies, the company said.

NORTHBROOK, Ill. — The U.S. subsidiary of Japanese drug maker Astellas Pharma has made a drug for overactive bladder available in U.S. pharmacies, the company said.

Astellas Pharma US announced the availability of Myrbetriq (mirabegron) extended-release tablets. The drug is used to treat OAB with symptoms of urge urinary incontinence, urgency and urinary frequency. The Food and Drug Administration approved the drug on June 28, 2012.

August 15, 2012
FDA approves Wockhardt enlarged prostate drug

The Food and Drug Administration has approved a drug for enlarged prostate made by generic drug maker Wockhardt, the company said.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a drug for enlarged prostate made by generic drug maker Wockhardt, the company said.

Wockhardt, based in Mumbai, India, announced the approval of alfuzosin hydrochloride extended-release tablets in the 10-mg strength, which is designed to treat enlarged prostate, also known as benign prostatic hyperplasia.

The drug is a generic version of Sanofi's Uroxatral. Various versions of the drug have sales of about $81.5 million, according to IMS Health.

August 3, 2012
Drug for overactive bladder effective in patients who haven't responded well to earlier therapy, study finds

A drug made by Pfizer and used to treat overactive bladder was effective in reducing leakage of urine in patients with the disorder, according to the results of a post-approval clinical study.

NEW YORK — A drug made by Pfizer and used to treat overactive bladder was effective in reducing leakage of urine in patients with the disorder, according to the results of a post-approval clinical study.

Pfizer announced Friday results of a phase-4 study of Toviaz (fesoterodine fumarate) in the reduction of urge urinary incontinence in patients with OAB who had a less than 50% reduction in UUI when taking Detrol LA (tolterodine tartrate), a commonly prescribed treatment for the condition also made by Pfizer.

July 27, 2012
Study: Men with prostate cancer more likely to die from other causes

Men diagnosed with prostate cancer are less likely to die from the disease than from such preventable conditions as heart disease, according to a new study from Harvard School of Public Health.

BOSTON — Men diagnosed with prostate cancer are less likely to die from the disease than from such preventable conditions as heart disease, according to a new study from Harvard School of Public Health.

July 26, 2012
Safeway raises $9 million for prostate cancer awareness

Safeway has raised more than $9 million during its month-long prostate cancer awareness campaign.

PLEASANTON, Calif. — Safeway has raised more than $9 million during its month-long prostate cancer awareness campaign.

July 6, 2012
Study: Diabetes drugs may be associated with increased bladder cancer risk

A drug commonly used to treat diabetes may be associated with an increased risk of bladder cancer, according to a new study published in the Canadian Medical Association Journal.

NEW YORK — A drug commonly used to treat diabetes may be associated with an increased risk of bladder cancer, according to a new study published in the Canadian Medical Association Journal.

June 28, 2012
FDA approves overactive bladder drug made by Astellas

The Food and Drug Administration has approved a new drug for treating overactive bladder made by Astellas Pharma, the agency said Thursday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating overactive bladder made by Astellas Pharma, the agency said Thursday.

The FDA announced the approval of Myrbetriq (mirabegron), which works by relaxing the bladder muscle while the organ is filling. In patients with overactive bladder, the muscle can't be controlled, squeezes too often or squeezes without warning. Symptoms of overactive bladder include the need to urinate too often, the need to urinate immediately and incontinence. The condition affects about 33 million Americans.

June 13, 2012
Fans for the Cure partners with Walgreens on prostate cancer awareness baseball tour

Ed Randall's Fans for the Cure on Wednesday announced that it once again has teamed with Walgreens to increase awareness about prostate cancer in baseball ballparks across the United States.

NEW YORK — Ed Randall's Fans for the Cure on Wednesday announced that it once again has teamed with Walgreens to increase awareness about prostate cancer in baseball ballparks across the United States. For the second year, Fans for the Cure and Walgreens are sponsoring a Baseball Road Trip, designed to strike out prostate cancer by encouraging men to "visit your doctor to check for prostate cancer, get your PSA score and stay in the game."

The road trips kicks off on Father's Day, June 17.

June 5, 2012
Safeway kicks off annual prostate cancer awareness campaign

Safeway and its charitable arm have launched their annual prostate cancer awareness campaign this month.

PLEASANTON, Calif. — Safeway and its charitable arm have launched their annual prostate cancer awareness campaign this month.

May 31, 2012
Sam's Club to host men's health screenings

Sam's Club is marking Men's Health Month in June by offering free men's health screenings at its pharmacies.

BENTONVILLE, Ark. — Sam's Club is marking Men's Health Month in June by offering free men's health screenings at its pharmacies.

May 23, 2012
Heart disease, cancer lead fatalities in men 45+

All men know: It’s not the fall that kills you; it’s that sudden stop at the end. Men smoke more, drink more and eat more. Men die sooner and are less likely to seek health care on their own. Men are full-throttle all-systems-go, until one day they’re not. Because it’s that sudden run-in with a heart attack or stroke, that sudden diagnosis of prostate or colon cancers, that slows them down.

All men know: It’s not the fall that kills you; it’s that sudden stop at the end. Men smoke more (23.2% versus 18.1% of women), drink more (71.6% versus 59.6%) and eat more (40% overweight, 21.5% obese versus 28.6% and 17.6%, respectively). Men die sooner (before the age of 75 years versus age 80 years for women) and are less likely to seek health care on their own (25.3% of men have no usual source of health care versus 13.8% of women).

April 6, 2012
FDA advisory committee recommends approval for Astellas overactive bladder drug

A panel of Food and Drug Administration experts has recommended approval for a drug made by Astellas Pharma for overactive bladder.

DEERFIELD, Ill. — A panel of Food and Drug Administration experts has recommended approval for a drug made by Astellas Pharma for overactive bladder.

The drug maker announced that the FDA Reproductive Health Drugs Advisory Committee voted 7-4 with one abstention that its assessment of the risks and benefits of the drug YM178 (mirabegron) supported the drug's approval.

The FDA is not required to follow the recommendations of advisory committees, but usually does. The agency is expected to decide whether or not to approve the drug by June 29.

December 9, 2011
FDA approves Antares Pharma's overactive bladder drug

The Food and Drug Administration has approved a topical gel made by Antares Pharma for overactive bladder.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a topical gel made by Antares Pharma for overactive bladder.

Watson Pharmaceuticals announced Thursday the approval of oxybutynin gel in the 3% strength, which it will launch next year under a licensing agreement with Antares.

December 6, 2011
Pfizer's Toviaz safe, effective in treating overactive bladder in elderly patients

A drug made by Pfizer appears to work in treating overactive bladder in elderly patients, according to results of a clinical trial released Monday.

NEW YORK — A drug made by Pfizer appears to work in treating symptoms of overactive bladder in elderly patients, according to results of a clinical trial released Monday.

Pfizer said that results of study A0221049 of the drug Toviaz (fesoterodine fumarate) worked better than placebo in reducing the number of urgency urinary incontinence episodes. The 12-week study enrolled 562 elderly people in the United States. The drug already has Food and Drug Administration approval for treating overactive bladder.

November 21, 2011
Amgen drug reduces risk of prostate cancer spreading to bones, study finds

A drug made by Amgen delayed the spread of prostate cancer to the bones in men with the disease and prolonged the survival of men with the condition, according to results of a late-stage clinical trial.

THOUSAND OAKS, Calif. — A drug made by Amgen delayed the spread of prostate cancer to the bones in men with the disease and prolonged the survival of men with the condition, according to results of a late-stage clinical trial.

October 12, 2011
Lilly drug effectively treats enlarged prostate, study finds

A drug made by Eli Lilly & Co. produced "significant" improvements in patients with erectile dysfunction who also had benign prostatic hyperplasia, according to results of a new study.

INDIANAPOLIS — A drug made by Eli Lilly & Co. produced "significant" improvements in patients with erectile dysfunction who also had benign prostatic hyperplasia, according to results of a new study.

The phase-3 study, published in the Journal of Sexual Medicine, found that Cialis (tadalafil) improved erectile dysfunction and benign prostatic hyperplasia in men with both conditions. BPH is a condition in which the prostate enlarges, causing urinary symptoms.

October 12, 2011
NIH study links vitamin E supplementation to prostate cancer

A National Institutes of Health study published Tuesday in the Journal of the American Medical Association established a link between vitamin E supplementation and prostate cancer.

BETHESDA, Md. — A National Institutes of Health study published Tuesday in the Journal of the American Medical Association established a link between vitamin E supplementation and prostate cancer. Men who took 400 international units of vitamin E daily had more prostate cancers compared with men who took a placebo, according to an updated review of data from the Selenium and Vitamin E Cancer Prevention Trial, the NIH stated.

October 7, 2011
Lilly's Cialis approved for benign prostatic hyperplasia

The Food and Drug Administration has approved a new use for a drug made by Eli Lilly for erectile dysfunction, Lilly said Friday.

INDIANAPOLIS — The Food and Drug Administration has approved a new use for a drug made by Eli Lilly for erectile dysfunction, Lilly said Friday.

The FDA approved Cialis (tadalafil) as a once-daily treatment for men with erectile dysfunction and benign prostatic hyperplasia, also known as BPH, as well as for BPH alone. BPH is a condition in which the prostate enlarges, which can cause urinary symptoms.

September 29, 2011
DSE Healthcare employs social media to elicit consumer testimonials

DSE Healthcare Solutions reached out to volunteers with recurrent urinary tract infections through social media sites for a 12-week Cystex challenge.

EDISON, N.J. — DSE Healthcare Solutions reached out to volunteers with recurrent urinary tract infections through social media sites for a 12-week Cystex challenge. The outreach incorporated the Cystex Facebook page, Cystex Ladies Room Blog and outreach to bloggers, who spread the word through their network of consumers and other bloggers.

September 13, 2011
Impax confirms patent challenge for generic Jalyn

Impax Labs has hit a roadblock in its attempt to market a generic version of a symptomatic benign prostatic hyperplasia drug.

HAYWARD, Calif. — Impax Labs has hit a roadblock in its attempt to market a generic version of a symptomatic benign prostatic hyperplasia drug.

August 12, 2011
Mylan ships generic prostate drug

Generic drug maker Mylan has begun shipping a drug for enlarged prostate, the company said Friday.

PITTSBURGH — Generic drug maker Mylan has begun shipping a drug for enlarged prostate, the company said Friday.

Mylan announced the launch of alfuzosin hydrochloride extended-release tablets in the 10-mg strength.

The drug is a generic version of Sanofi's Uroxatral, which had sales of about $241 million during the 12-month period ended in June, according to IMS Health.

July 18, 2011
Safeway raises more than $10.1 million for prostate cancer research

Safeway on Monday announced that its month-long prostate cancer campaign raised nearly $10.1 million as part of the company’s ongoing effort to fund research geared toward finding a cure for the leading cancer affecting men.

PLEASANTON, Calif. — Safeway on Monday announced that its month-long prostate cancer campaign raised nearly $10.1 million as part of the company’s ongoing effort to fund research geared toward finding a cure for the leading cancer affecting men.

June 22, 2011
Endo completes acquisition of American Medical Systems

Endo Pharmaceuticals has acquired a provider of devices and therapies for male and female pelvic health.

CHADDS FORD, Pa. — Endo Pharmaceuticals has acquired a provider of devices and therapies for male and female pelvic health.

Endo said its acquisition of American Medical Systems has boosted the drug maker's devices and services business segment, and the combination of AMS with Endo's existing platform will provide additional cost-effective solutions across the entire urology spectrum.

The company announced its definitive agreement to acquire AMS in a cash transaction valued for approximately $2.9 billion.